Abiopharma

🔍 Finley John David (Director)

Company: PALISADE BIO, INC. (PALI)

Report Date: 2026-02-11

Detailed Transactions and Holdings:

• Acquired 13,333 shares of Common Stock (Direct)
  Date: 2026-02-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 31,249.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2
• Sold 3,896 shares of Common Stock at $1.75 per share (Direct)
  Date: 2026-02-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 27,353.00 | transaction_form_type: 4 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-02-11 | Code: H | nature_of_ownership: By FCW Investments, LLC | shares_owned_after: 51.00 | Footnotes: F4
• Sold 13,333 shares of Restricted Stock Units (Derivative)
  Date: 2026-02-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 26,667.00 | transaction_form_type: 4 | Footnotes: F5, F6, F6

Footnotes:

• F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 11, 2025.
• F2: Includes 4,444 shares acquired under the Issuer's Employee Stock Purchase Plan on November 20, 2025.
• F3: The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• F4: Reporting Person is the managing member of FCW Investments, LLC and has the sole investment and voting power over the securities held by this entity.
• F5: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• F6: The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.